Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess Response to Tamoxifen in (cT3)/ Inoperable Locally Advanced / Metastatic ER-positive Breast Cancer by the 'Tamoxifen Activity Score' Based on Drug Interaction and Polymorphisms in Genes Coding for Tam. Metabolising Enzymes.

NCT00965939 is registered in ClinicalTrials.gov with Vlaamse Vereniging voor Obstetrie en Gynaecologie as lead sponsor.

NCT NCT00965939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00965939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess Response to Tamoxifen in (cT3)/ Inoperable Locally Advanced / Metastatic ER-positive Breast Cancer by the 'Tamoxifen Activity Score' Based on Drug Interaction and Polymorphisms in Genes Coding for Tam. Metabolising Enzymes.
Lead sponsor
Vlaamse Vereniging voor Obstetrie en Gynaecologie
Phase
Observational
Overall status
Completed
Start date
February 28, 2009
Completion date
Not reported
Enrollment
300 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

er-positive breast cancer